

1 Title: **Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal**  
2 **route among adult who had received CoronaVac**

3

4 Authors:

5 Rapisa Nantanee, MD<sup>a,b</sup>, Puneyavee Aikphaibul, MD<sup>a,c</sup>, Peera Jaru-Ampornpan, PhD<sup>d</sup>, Pimpayao  
6 Sodsai, PhD<sup>e</sup>, Orawan Himananto, PhD<sup>f</sup>, Tuangtip Theerawit, RN<sup>a</sup>, Jiratchaya Sophonphan,  
7 MSc<sup>g</sup>, Punyot Tovichayathamrong, MD<sup>h</sup>, Kasama Manothummetha, MD<sup>h</sup>, Tysdi Laohasereekul,  
8 MD<sup>h</sup>, Narin Hiransuthikul, MD, PhD<sup>i</sup>, Nattiya Hirankarn, MD, PhD<sup>e</sup>, Thanyawee Puthanakit,  
9 MD<sup>a</sup> on behalf of the Study Team\*

10

11 <sup>a</sup> Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University,  
12 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

13 <sup>b</sup> Pediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and  
14 Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King  
15 Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873, Rama IV Rd,  
16 Pathumwan, Bangkok, 10330, Thailand

17 <sup>c</sup> Division of Pediatric Dermatology, Department of Pediatrics, Faculty of Medicine,  
18 Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross  
19 Society, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

20 <sup>d</sup> Virology and Cell Technology Research Team, National Center for Genetic Engineering and  
21 Biotechnology (BIOTEC)

22 <sup>e</sup> Center of Excellence in Immunology and Immune-mediated Diseases, Department of  
23 Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV Rd, Pathumwan,  
24 Bangkok, 10330, Thailand

25 <sup>f</sup> Monoclonal Antibody Production and Application Research Team, National Center for Genetic  
26 Engineering and Biotechnology (BIOTEC)

27 <sup>g</sup> The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red  
28 Cross AIDS Research Centre, Bangkok, Thailand

29 <sup>h</sup> Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 1873, Rama IV  
30 Rd, Pathumwan, Bangkok, 10330, Thailand

31 <sup>i</sup> Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn  
32 University, 1873, Rama IV Rd, Pathumwan, Bangkok, 10330, Thailand

33

34 **Corresponding author:** Thanyawee Puthanakit, MD

35 Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics,  
36 Faculty of Medicine, Chulalongkorn University

37 1873, Rama IV Rd., Pathumwan, Bangkok, 10330, Thailand.

38 Telephone: (+66)2-2564930

39 E-mail: [thanyawee.p@chula.ac.th](mailto:thanyawee.p@chula.ac.th)

40 \*Additional study team members are listed.

41

#### 42 **Highlights:**

- 43 • Intradermal AZD1222 booster vaccine gave comparable short-term immunogenicity but  
44 lower 90-day immunogenicity with conventional intramuscular vaccine.

45       • Lower systemic but higher local reactogenicity was found in intradermal AZD1222

46       booster vaccine.

47       • Blister and pruritus could be seen after intradermal AZD1222 booster vaccine.

48

49   Word counts: 3295, Abstract 300

50   41 References, 2 Tables, 3 Figures, 1 Supplementary Table, 1 Supplementary Figure

51   Thai clinical trial registry: TCTR 20210817003

52 **Abstract**

53 **Background**

54 Currently, booster dose is needed after 2 doses of inactivated COVID-19 vaccine. With limited  
55 resource and shortage of COVID-19 vaccine, intradermal(ID) administration might be a potential  
56 dose-sparing strategy.

57 **Objective**

58 To determine antibody response and reactogenicity of ID ChAdOx1 nCoV-19  
59 vaccine(AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose  
60 CoronaVac(SV) in healthy adult.

61 **Methods**

62 This is a prospective cohort study of adult aged 18-59 years who received 2-dose SV at 14-35  
63 days apart for more than 2 months. Participants received ID AZD1222 at fractional low  
64 dose( $1 \times 10^{10}$  viral particles,0.1ml). Antibody responses were evaluated by surrogate virus  
65 neutralization test(sVNT) against wild type and delta variant and anti-spike-receptor-binding-  
66 domain immunoglobulin G(anti-S-RBD IgG) at prior, day14 or 28, and day90 post booster.  
67 Solicited reactogenicity was collected during 7 days post-booster. Primary endpoint was the  
68 differences of sVNT against delta strain  $\geq 80\%$  inhibition at day14 and 90 compared with the  
69 parallel cohort study of 0.5-ml intramuscular(IM) route.

70 **Results**

71 From August2021, 100 adults with median(IQR) age of 46(41-52) years participated. At  
72 baseline, geometric means(GMs) of sVNT against delta strain prior to booster were  
73 22.4%inhibition(95%CI 18.7-26.9) and of anti-S-RBD IgG were 109.3(95.4-125.1)BAU/ml.  
74 GMs of sVNT against delta strain were 92.9%inhibition(95%CI 87.7-98.3) at day14 and

75 73.1% inhibition(66.7-80.2) at day90 post ID booster. The differences of proportion of  
76 participants with sVNT to delta strain  $\geq 80\%$  inhibition in ID recipients versus IM were  
77 +4.2%(95%CI-2.0to10.5) at day14, and -37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs  
78 were 2037.1(95%CI1770.9-2343.2) at day14 and 744.6(650.1-852.9) BAU/ml at day90,  
79 respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83-1.20) at day14,  
80 and 0.82(0.66-1.02) at day90. Only 18% reported feverish, compared with 37% of IM( $p=0.003$ ).  
81 Only 18% reported feverish, compared with 37% of IM( $p=0.003$ ). Common reactogenicity was  
82 erythema(55%) at injection site while 7% reported blister.

### 83 **Conclusion**

84 Low-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared  
85 with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity.

86

87 **Keywords:** SARS-CoV2 vaccine, booster dose, AZD1222, Neutralizing antibody titer, anti-  
88 SARS CoV2 IgG, CoronaVac vaccine, ChAdOx1 nCoV-19 vaccine, intradermal

89

### 90 **Abbreviations:**

91 BAU = Binding-antibody unit

92 BMI = Body mass index

93 CMI = Cell-mediated immunity

94 ELISpot = Enzyme-linked immunospot

95 GM = Geometric mean

96 GMR = Geometric mean ratio

- 97 ID = Intradermal
- 98 IM = Intramuscular
- 99 PBMC = Peripheral blood mononuclear cell
- 100 SFU = Spot forming unit
- 101 S-RBD = Spike receptor binding domain
- 102 sVNT = Surrogate virus neutralization test

103 **1. Introduction**

104 Global report of Coronavirus disease (COVID-19) infection was over 250 million cases  
105 with more than 5 million deaths [1], despite over 7 billion doses of vaccination have been  
106 administered. In Thailand, as of November 2021, more than 2 million reported COVID-19  
107 infection with over 20,000 deaths. Inactivated COVID-19 vaccine, CoronaVac (Sinovac Life  
108 Sciences, Beijing, China), was used for mass vaccination in several countries e.g., Thailand,  
109 China, Brazil, and Chile. Effectiveness of CoronaVac for prevention of COVID-19 was 65.9%  
110 from study in Chile [2] and 36.8% from study in Brazil [3]. With the rising of delta variant  
111 (B.1.617.2) of SAR-CoV-2 globally, the neutralizing activity induced by CoronaVac declined  
112 [4]. Hence, heterologous prime boost vaccination may provide better immunogenicity. With  
113 AZD1222 followed by BNT162b2 heterologous prime boost vaccination, this vaccination  
114 strategy provided highest T cell reactivity compared with homologous vaccination [5, 6].

115 Standard administration of currently available COVID-19 vaccine is via intramuscular  
116 injection. Routes for vaccine administration could be intramuscular (IM), intradermal (ID) in  
117 which efficacy is related to the immunogenicity [7]. ID administration offers potential dose-  
118 sparing benefit compared with intramuscular administration, rabies vaccination as example. ID  
119 vaccination is a technique in which the vaccine is administered into dermis which is rich in  
120 antigen presenting cells such as dermal dendritic cells [8]. Because of the abundance of antigen  
121 presenting cells in skin, ID administration required less antigenic dose (usually 20%-30% of  
122 standard dose) to induce immune responses than standard IM vaccination. Many studies showed  
123 effective immune response by ID vaccination including influenza, rabies, hepatitis B, Bacille  
124 Calmette-Guerin (BCG), and polio vaccination [7, 9-12]. For influenza vaccine, a systematic  
125 review and meta-analysis showed comparable seroprotection rates for 9- $\mu$ g ID with 15- $\mu$ g IM

126 injection with higher local adverse event particularly erythema and swelling [9]. For rabies  
127 vaccine, ID schedules offer advantages through savings in costs, doses and time as recommended  
128 by WHO and also approved use on label of vaccine [12].

129 Fractionated-dose ID COVID-19 vaccine is the potential for rapid achievement of herd  
130 immunity based on other vaccines reported [7]. Study of one-tenth dose of mRNA-1273 ID  
131 vaccination showed comparable anti-spike IgG and anti-RBD IgG responses to conventional IM  
132 vaccination at 2 weeks post primary vaccination series [13]. However, one-fifth dose of  
133 BNT162b2 ID booster in healthy Thai adult post 2-dose CoronaVac failed to boost T cell  
134 response at 14 days, despite robust neutralizing antibodies response [14]. A case report of ID  
135 AZD1222 after 2 doses of CoronaVac showed increase of antibodies and T cell responses against  
136 spike protein which neutralizing antibody increased to almost 100% with minimal local reaction  
137 at 2-3 weeks after booster [15].

138 This study aims to evaluate immunogenicity and reactogenicity of ID AZD1222 booster  
139 dose in adults who had received 2 doses of CoronaVac.

140



## 141 **2. Methods**

### 142 **2.1 Study design and participants**

143 This study was conducted at Chulalongkorn University Health Center, Faculty of  
144 Medicine, Chulalongkorn University, Bangkok Thailand. This is a prospective cohort study. The  
145 participants who aged 18 – 59 years old and received two doses of CoronaVac for at least 60  
146 days, 14 – 35 days apart were included in this study. The exclusion criteria were receiving any  
147 immunosuppressants or blood products within 3 months before the enrollment or receiving any  
148 vaccines within 2 weeks. All participants gave written informed consent prior to study  
149 enrollment.

150 This study was registered in Thai Clinical Trials Registry ([thaiclinicaltrials.org](http://thaiclinicaltrials.org), TCTR  
151 20210817003). Immunogenicity parameters were compared with the parallel randomized  
152 controlled trial on healthy adult with standard dose and low dose IM administration of AZD1222  
153 booster after completing 2 doses of CoronaVac (TCTR20210722003), conducted at same  
154 settings and lab. We compared the results of this study with conventional standard dose (0.5 ml)  
155 IM group. Institutional review board of Faculty of Medicine, Chulalongkorn University  
156 approved this study (IRB no. 663/64) and parallel IM AZD1222 booster study (IRB no. 600/64).  
157

### 158 **2.2 Study procedures**

159 One hundred participants were recruited in this study. At baseline, the history of SARS-  
160 CoV-2 vaccination and exposure to confirmed case within 3 months were taken. Blood sample  
161 was collected prior to giving a booster dose. The participants received ID AZD1222 lot number  
162 A1009, manufactured by Siam Bioscience Co., Ltd., 0.1 ml ( $1 \times 10^{10}$  viral particles). The  
163 vaccination was performed by trained physician/nurse (RN and TT). The solicited local and

164 systemic reactogenicity during 7 days after vaccination was recorded in the diary. The solicited  
165 reactogenicity included fever, pain, swelling, erythema, headache, malaise, myalgia, arthralgia,  
166 vomiting, and diarrhea. Scheduled visits were day 14 for 50 participants, day 28 for 50  
167 participants. At day 90, 40 participants were scheduled, to collect reactogenicity data and  
168 perform blood collection.

169 The cell-mediated immunity (CMI) sub study was performed among 20 participants, at  
170 baseline, day 28, and day 90, with enzyme-linked immunospot (ELISpot) assay to evaluate T and  
171 B cell responses.

172

### 173 **2.3 Immunogenicity outcomes**

174 All participants' samples were tested for spike receptor binding domain (S-RBD) IgG,  
175 and functional neutralizing antibody (NAb) against SARS-CoV-2 wild type and delta variants by  
176 surrogate virus neutralization test (sVNT). All of the immunogenicity results in ID group were  
177 compared with IM participants at equivalent time points.

178

#### 179 Quantitative spike receptor binding domain IgG (anti-S-RBD IgG) ELISA

180 The ELISA protocol was adapted from Amanat *et al.* (2020) [16]. Briefly, diluted serum  
181 samples were incubated in 96-well plates coated with purified recombinant Myc-His-tagged S-  
182 RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1). Then, ELISA was performed. Anti-  
183 S-RBD IgG level was reported in binding-antibody units (BAU/mL) following conversion of  
184 OD450 values with the standard curve using known units of WHO international standard  
185 (NIBSC 20/136). We used anti-S-RBD IgG level at 506 BAU/ml, which is correlated with 80%  
186 vaccine efficacy reported by the Oxford COVID vaccine trial group [17], as a cut off.

187

188 Surrogate virus neutralization test (sVNT)

189 A surrogate virus neutralization test was set up as previously described in Tan *et al.*  
190 (2020) [18]. Recombinant SRBD from the wild-type (Wuhan-Hu-1) and delta (B.1.617.2) strains  
191 were used. Serum samples - SRBD mixture were incubated in 96-well plates coated with 0.1  
192  $\mu\text{g}/\text{well}$  recombinant human ACE2 ectodomain (GenScript). Then, ELISA was performed. The  
193 negative sample was pre-2019 human serum. The % inhibition was calculated as follows:

$$\%inhibition = 100 \times \left[ 1 - \frac{sampleOD450}{negativeOD450} \right]$$

194 Enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses

195 For T cell, ELISpot assay using a Human IFN- $\gamma$  ELISpotPro™ kit (Mabtech, Stockholm,  
196 Sweden) was used for SARS-CoV-2-specific T cell responses in fresh peripheral blood  
197 mononuclear cells (PBMCs). Briefly,  $2.5 \times 10^5$  PBMCs were stimulated in AIM-V medium  
198 with overlapping peptide pool from 100 peptides of SARS-CoV-2 Spike (S) defined peptides and  
199 101 peptides from the nucleoprotein (N), membrane protein (M), open reading frame proteins  
200 (O) (Mabtech, Stockholm, Sweden) at a final concentration of 2  $\mu\text{g}/\text{ml}$  for 20 hours. Negative  
201 control and positive control, anti-CD3, were also included. The spots were counted using  
202 ImmunoSpot analyzer. Spot counts for negative control wells were subtracted from the test wells  
203 to generate normalized readings, these are presented as spot forming unit (SFU) per million  
204 PBMCs.

205 For B cells, Human IgG SARS-CoV-2 RBD ELISpot PLUS (ALP) kit (Mabtech,  
206 Stockholm, Sweden) was used for SARS-CoV-2-specific B cell responses. Briefly, the memory  
207 B cells were differentiated into antibody secreting cells by pre-stimulating the fresh PBMCs with  
208 R848 and IL-2 for 72 hours. Unstimulated well was also used as negative control. Stimulated and

209 unstimulated PBMCs ( $5 \times 10^5$  cells per well) were added into ELISpot plate and incubated for  
210 18 hours. An RBD-WASP antigen was added into RBD-specific IgG detected well while  
211 MT78/145- biotinylated antibodies were added into total IgG detected well, positive control.  
212 Anti-WASP-ALP was added into RBD-specific IgG detected well and negative control well  
213 while streptavidin-ALP was added into total IgG detected well. Spot counting was performed in  
214 the same method as T cells.

215

## 216 **2.4 Reactogenicity**

217 Solicited reactogenicity was recorded by participants using diary. All symptoms were  
218 graded in 3 grades [19]: grade 0 for no symptom; grade 1 for mild symptom, which was not  
219 interfere with activities or vomiting 1 – 2 times/day or diarrhea 2 – 3 times/day; grade 2 for  
220 moderate symptom, which interfered with activities or need to take medication, or vomiting  
221 more than 2 times/day or diarrhea 4 – 5 times/day; grade 3 for severe symptom, which  
222 incapacitated or need hospitalization or diarrhea 6 or more times/day. Fever was graded as grade  
223 1 ( $38.0 - 38.4^\circ\text{C}$ ), grade 2 ( $38.5 - 38.9^\circ\text{C}$ ), grade 3 ( $39 - 40^\circ\text{C}$ ), and grade 4 (more than  $40^\circ\text{C}$ ).  
224 Unsolicited adverse events were also recorded at all visits by study team.

225

## 226 **2.5 Statistical analysis**

227 Demographic and clinical characteristics were described for the subjects. Continuous  
228 variables were expressed as median (interquartile range: IQR) and number with percentage for  
229 categorical variables. Differences in continuous and categorical variables between two groups  
230 were assessed using a Wilcoxon rank sum test, Chi-square test, or fisher exact test, respectively.  
231 The sVNT results, to either wild type or delta strain, of more than 80% were used to classify the

232 achievement of 80% protection against symptomatic infection. The anti-S-RBD IgG of more  
233 than 506 BAU/ml were used in this study as a cut off for protective antibody level, which  
234 previously reported to be associated with 80% vaccine efficacy against primary symptomatic  
235 COVID-19 [20].

236 We presented primary comparisons between ID and IM group in terms of the differences  
237 of proportion of participants achieving sVNT  $\geq$ 80% inhibition. Non-inferiority was concluded if  
238 the lower bound of the 95% CI did not exceed -10%. Geometric means (GMs) and geometric  
239 mean ratios (GMRs) with 95% confidence interval of anti-S-RBD IgG and sVNT, at day 0, 14,  
240 28, and 90 after booster vaccination, were calculated. Non-inferiority was concluded if the lower  
241 bound of the 95% CI did not exceed 0.67 for the GMR of anti-S-RBD. All P-values reported are  
242 two-sided. Statistical significance was defined as  $P < 0.05$ . Stata version 15.1 (Stata Corp.,  
243 College Station, Texas), was used for analysis.

244

## 245 **3. Results**

### 246 **3.1 Baseline characteristic**

247 The participants were enrolled during August 2021. The demographic data was shown in  
248 Table 1. Median age was 46 (IQR 41-52) years, 55% were male. Underlying disease was  
249 described, as shown in Table 1. Duration between 2 doses of CoronaVac was 21 days with  
250 median 71 (IQR 65-76) days prior to ID booster administration. The sVNT against delta strain  
251 GM was 44.5% inhibition and against wild type was 22.4% inhibition. The number of female  
252 were higher in IM cohort, while the interval between completion of 2-dose CoronaVac and  
253 AZD1222 booster was longer in ID than IM cohort.

254

### 255 **3.2 Reactogenicity**

256 Most common solicited reactogenicity reported was localized at injection site such as  
257 erythema and pain, as shown in Figure 1 and Supplementary Table 1. More than half (53%)  
258 participants reported erythema, lasting for median duration of 4 (IQR 3-6) days, which was  
259 mostly grade 1. Pain at injection site was reported in 43% with median duration of 2 (IQR 1-4)  
260 days and mostly grade 1. Other solicited reactogenicity reported were 40% fatigue, 30% myalgia,  
261 27% headache, 18% feverish, 17% swelling, 12% arthralgia and 9% diarrhea. Vesicle and blister  
262 at injection site, which progressed to dry blister and turned to hyperpigmentation, were also  
263 reported as unsolicited reactogenicity (photo as shown in Supplementary Figure 1).

264 Lower systemic reactogenicity including fever (0% ID versus 27% IM,  $p = N/A$ ), feverish  
265 (18% ID versus 37% IM,  $p = 0.003$ ), headache (27% ID versus 64% IM,  $p < 0.001$ ), fatigue (40%  
266 ID versus 68% IM,  $p < 0.001$ ), and myalgia (30% ID versus 69% IM,  $p < 0.001$ ) was reported in  
267 ID compared with IM, as shown in Supplementary Table 1.

268

### 269 **3.3 Immunogenicity of ID booster**

#### 270 **3.3.1 sVNT**

271 Ninety-eight percent of the participants achieved sVNT against delta strain and wild type  
272  $\geq 80\%$  inhibition at both day 14 and day 28. The GMs (95% CI) of sVNT to delta strain were  
273 95.5% inhibition (94.2-96.8) at day 14, and 93.7% inhibition (91.9-95.5) at day 28 after ID  
274 booster, as shown in Figure 2 and Table 2. The GMs (95% CI) of sVNT to wild type were 94.8%  
275 inhibition (94.0-95.6) at day 14, and 93.7% inhibition (92.1-95.4) at day 28, as shown in Table 2.  
276 At day 90 post booster vaccination, the GMs of sVNT, to both delta strain and wild type, waned  
277 to 73.1% inhibition (66.7-80.2) and 81.9% inhibition (76.2-88.0), respectively.

278

#### 279 **3.3.2 Anti-S-RBD IgG**

280 The GMs (95% CI) of anti-S-RBD IgG were 2037.1 (1770.9-2343.2), 1084.9 (970.0-  
281 1213.4), and 744.6 (650.1-852.9) BAU/mL at day 14, 28, and 90 after ID booster, respectively,  
282 as shown in Table 2.

283

### 284 **3.4 Immunogenicity of ID compared with IM booster**

285 Proportion of participants with sVNT to delta strain  $\geq 80\%$  inhibition at day 14 was non-inferior  
286 among ID recipients compared with IM recipients, with difference of 4.2% (95% CI -2.0 to  
287 10.5). But at day 90, it was significantly lower, with difference of -37.3% (-54.2 to -20.3). These  
288 differences were similar to sVNT to wild type, as shown in Table 2. GMR of anti-S-RBD IgG  
289 showed non-inferiority at day 14, with GMR of 0.99 (0.83-1.20), and borderline inferior at day

290 90, with GMR of 0.82 (0.66-1.02). However, at 90 days after ID vaccination, only 79.5% had  
291 antibody exceeding the proposed protective level, compared with 83.8% of IM recipients.

292

### 293 **3.5 T and B cell responses evaluated by ELISpot assay**

294 From the sub study analysis of CMI response, ELISpot assay showed significant rise of T  
295 cell and B cell response at day 28 and declined at day 90, as shown in Figure 3. Median (IQR) of  
296 IFN- $\gamma$ -producing T cell spots specific to SNMO protein-derived peptide pools at day 0 was 32  
297 (14-56), at day 28 was 146 (70-192), and at day 90 was 90 (20-140) SFU/10<sup>6</sup> PBMCs,  
298 respectively. Compared with IM study, the median (IQR) was 52 (40-48) at day 0, 96 (44-128) at  
299 day 28, and 44 (32-72) SFU/10<sup>6</sup> PBMCs at day 90, respectively. Median (IQR) of RBD-specific  
300 memory B cell spots at day 0 was 2 (0-10), increased to 18 (14-36) at day 28, and declined to 6  
301 (4-20) SFU/10<sup>6</sup> PBMCs at day 90. Compared with IM study of 4 (0-16) at day 0, 26 (16-32) at  
302 day 28, and 8 (4-16) SFU/10<sup>6</sup> PBMCs at day 90.

303



304 **4. Discussion**

305 ID AZD1222 booster vaccine in 2-dose-CoronaVac-primed adults raised high anti-S-  
306 RBD IgG >506 BAU/ml, and high levels of functional neutralizing antibodies >80% inhibition  
307 as measured by sVNT to wild type and delta strain, thus non-inferior to IM route at day 14.  
308 However, at 3 months post ID AZD1222 booster vaccination, this study demonstrated, despite  
309 similar anti-S-RBD IgG, but lower sVNT against delta strain to IM booster, suggesting more  
310 rapid waning neutralizing antibody response after ID compared to IM route. Most reactogenicity  
311 occurred locally with erythema, pain, and swelling at injection site. Erythema, swelling, and  
312 blister were reported more common in ID booster. Systemic symptoms such as fever, feverish,  
313 headache, fatigue, and myalgia were less common than conventional IM injection.

314 The non-inferior immunogenicity of ID vaccination was demonstrated for influenza,  
315 rabies, and hepatitis B vaccines [21]. Immunogenicity of ID AZD1222 at day 14 was not inferior  
316 to conventional IM booster vaccine as shown with GMR of anti-S-RBD and difference in  
317 proportion of participants having sVNT to delta strain and wild type passing 80%. This  
318 comparable result is similar to previous study in Netherland [22] which reported a robust  
319 antibody response from ID administration of mRNA COVID-19 vaccine at day 43 with  
320 comparable anti-spike IgG response for 10 µg ID with 100 µg IM mRNA-1273 vaccine.  
321 Additionally, recent report from Thailand also denoted a fractional-dose BNT162b2 ID booster,  
322 in healthy adults who had completed 2-dose inactivated vaccine for 2-3 months, induced  
323 comparable antibody level and function to the conventional IM booster when assessed on day 14  
324 and 28 [14]. To our knowledge, no published report demonstrated immunogenicity results at 3  
325 months post ID AZD1222 booster vaccination, which this study demonstrated inferior  
326 neutralizing antibodies.

327           Although, the importance of cellular immunity in correlation with vaccine protection is  
328 still unclear, specific T cells have been reported to reduce the severity of SARS-CoV-2 infection  
329 [23]. In this study, we have shown that a third dose of ID AZD1222 booster vaccine can  
330 increase specific T cell responses slightly higher than conventional IM route, similar to the  
331 previous report [24]. As opposed to previous ID BNT162b2 study, which failed to demonstrate T  
332 cell response, suggesting different vaccine platforms might play a role in cellular immune  
333 response. Specific memory B cells also have been reported to play a crucial role for effective  
334 responses to infection [25, 26]. Our result showed the slight boost of B cell response at 1 month  
335 and drop at 3 months, after ID AZD1222 booster. The timing of B cell study might be accounted  
336 for these responses, since the previous study showed the detectable B cell response after  
337 COVID-19 infection for 3-6 months [27].

338           This study reported local reactogenicity including erythema, blister, and pruritus after ID  
339 AZD1222 booster vaccine which is similar to previous report on rabies inactivated vaccine that  
340 more erythema and pruritus were reported from ID than conventional IM administration [28].  
341 Also blister formation was reported after BCG vaccination that evolved over two weeks into an  
342 ulcer at injection site [29]. ID influenza vaccine study reported significant higher local adverse  
343 events particularly erythema and swelling, and also more common of fever and chills which is  
344 different from this study that fever was more common in IM vaccination [9]. Hyperpigmentation  
345 was also reported in this study as still seen on day 28 follow up visit which previous study of  
346 hepatitis B vaccine reported of local hyperpigmentation after ID vaccination in 55% [30].  
347 Compared with parallel cohort IM study, ID booster had more local reactogenicity (erythema and  
348 swelling) at injection site but less pain and systemic reactogenicity (fatigue, myalgia, headache,  
349 feverish, arthralgia and diarrhea).

350 As current situation of COVID-19 pandemic, more vaccine supply is still needed for  
351 many countries as vaccine coverage is not enough to prevent mortality [31-33]. Almost half of  
352 the world population has received at least one dose of COVID-19 vaccine but only 2.2% of  
353 people in low-income countries have received vaccine [34]. AZD1222 or Astra Zeneca/Oxford  
354 COVID-19 vaccine has been used in Europe since December 2020 and also distributed in many  
355 countries including low to middle income countries [35]. As availability in many countries with  
356 limited vaccine supply, the ID administration of AZD1222 might be considered for mass  
357 vaccination as an advantage of dose-sparing technique [7]. However, there are some limitations,  
358 needs of skilled health providers for administration [36], and more rapid waning of neutralizing  
359 antibodies.

360 This study was limited by cohort study design without randomized control trial but there  
361 was the parallel cohort study with similar setting that should be able to benchmark the results.  
362 There were 2 factors that differed between the 2 groups. Specifically, there was more male in the  
363 ID group and the time interval between second and third dose was 1 week longer in the ID  
364 group. However, the immune responses at baseline before the third dose were comparable.  
365 Female was reported to have higher antibody response to vaccines [37] and after severe COVID-  
366 19 [38]. The finding of later inferior neutralizing antibodies might be attributed to this gender  
367 difference, specifically more male participants in ID cohort. This study chose to determine the  
368 levels of functional neutralizing antibodies using the surrogate virus neutralization assay, rather  
369 than standard live-virus neutralization assay. However, we used the high cut-off value at 80% of  
370 sVNT in this study. Moreover, good correlations between sVNT and live-virus neutralization  
371 have been exhibited elsewhere [18, 39-41]. The strengths of this study were reporting complete  
372 solicited reactogenicity of all 100 participants with ID booster vaccination and multiple methods

373 were used for immunity analysis including anti-S-RBD, sVNT (wild type and delta strain) and  
374 also CMI responses.

375           Intradermal AZD1222 booster vaccine in 2-dose-CoronaVac primed adult enhanced  
376 comparable short-term immunity, but inferior 3-month immunogenicity, with intramuscular  
377 administration. Reactogenicity was usually localized (erythema and pain) and less systemic than  
378 intramuscular vaccine. Due to more rapid waning neutralizing antibody, dose-sparing strategy  
379 with intradermal booster vaccination should be used in the setting of inadequate vaccine supply.

380

381

382 **Acknowledgements**

383 Thank you for all study teams for their assistance with the study.

384 Chulalongkorn University Health Service Center

385 Santhiti Dahlan, M.D., Preeyanuch Panchim, Ratchadaporn Bumrungpipattanaporn, RN,

386 Ampawan Sangchanpong, Wijitra Prayong

387 Department of Microbiology, Faculty of Medicine, Chulalongkorn University

388 Asst.Prof.Pokrath Hansasuta, M.D., Vichaya Ruenjaiman, PhD, Supapit Horpratum,

389 Jullada Thawilwang

390 Center of Excellence in Pediatric Infectious Diseases and Vaccines

391 Pintip Suchartlikitwong, M.D., Wipaporn Natalie Songtaweasin, M.D., Pathariya

392 Promsena, M.D., Monta Tawan, RN, Jitthiwa Athipunjapong, RN, Thutsanun

393 Meepuksom, RN, Angsumalin Sutjarit, RN, Juthamanee Moonwong, Rachaneekorn

394 Nadsasarn, Thidarat Jupimai, Pornpavee Nuncharoen, Sasiprapha Khamthi, Pathomchai

395 Amornrattanapajit, Phattharapa Khamkhen,

396 National Center for Genetic Engineering and Biotechnology (BIOTEC)

397 Anan Jongkaewwattana, PhD, Kirana Yoohat, Channarong Seepiban, Jaraspim Narkpuk,

398 Thorntun Deangphare,

399 Clinical Research Laboratory, Faculty of Medicine, Chulalongkorn University

400 Palida Pingthaisong, Suwat Wongmueng

401 Faculty of Medicine, Thammasat University

402 Asst.Prof.Sira Nantapisal, M.D., Ph.D.

403

404 **Funding**

405           The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under  
406 Health Research Platform (RA64/050), Chulalongkorn University. This research is also  
407 supported by Ratchadapisek Somphot Fund for Postdoctoral Fellowship, Chulalongkorn  
408 University.

409

410   **Conflict of interest**

411           The authors declare that they have no known competing financial interests or personal  
412 relationships that could have appeared to influence the work reported in this paper.

413

414 **Table 1.** Baseline characteristics of participants receiving AZD1222 booster vaccine after 2-dose  
 415 CoronaVac in healthy adults

Characteristic	ID (N = 100)	IM (N = 100)	p-value
<b>Gender</b>			
• Female, n (%)	45 (45)	61 (61)	0.02 <sup>†*</sup>
Age (years)	46 (41-52)	45 (34-50)	0.08 <sup>‡</sup>
BMI (kg/m <sup>2</sup> )	24.8 (21.4-27.4)	24.1 (21.6-26.9)	0.37 <sup>‡</sup>
<b>Underlying disease, n (%)</b>			
• Hypertension, n (%)	7 (7)	9 (9)	0.60 <sup>†</sup>
• Dyslipidemia, n (%)	6 (6)	7 (7)	0.77 <sup>†</sup>
• Diabetes mellitus, n (%)	6 (6)	3 (3)	0.31 <sup>†</sup>
• Allergic rhinitis, n (%)	1 (1)	2 (2)	0.56 <sup>†</sup>
Duration of 2 <sup>nd</sup> doses of CoronaVac and AZD1222 (days)	71 (65-76)	66 (62-74)	0.002 <sup>‡*</sup>
<b>Immunogenicity at baseline prior to booster</b>			
• sVNT-delta (% inhibition), GM (95%CI)	22.4 (18.7-26.9)	17.9 (14.3-22.5)	0.14 <sup>§</sup>
• sVNT-WT (% inhibition), GM (95%CI)	44.5 (40.6-48.7)	41.8 (37.1-47.1)	0.41 <sup>§</sup>
• Anti-S-RBD (BAU/mL), GM (95%CI)	109.3 (95.4-125.1)	98.9 (85.8-113.9)	0.31 <sup>§</sup>
• SNMO-specific T cell response (SFU/10 <sup>6</sup> PBMCs)	32 (14-56) (n = 20)	52 (40-84) (n = 19)	0.05 <sup>‡</sup>
• RBD-specific B cell response (SFU/10 <sup>6</sup> PBMCs)	2 (0-10) (n = 20)	4 (0-16) (n = 19)	0.50 <sup>‡</sup>

416 All data are reported as median (IQR), unless otherwise indicated.

417 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, BMI: Body  
418 mass index, GM: Geometric mean, ID: intradermal, IM: intramuscular, IQR: interquartile range,  
419 RBD: receptor binding domain, SNMO: Spike (S) nucleoprotein (N), membrane protein (M),  
420 and open reading frame proteins (O) of SARS-CoV-2, sVNT-delta: Surrogate virus  
421 neutralization test against delta strain, sVNT-WT: Surrogate virus neutralization test against wild  
422 type  
423 <sup>†</sup>Chi-square  
424 <sup>‡</sup>Wilcoxon rank sum test  
425 <sup>§</sup>Two sample independent t test  
426 \*p < 0.05



427 **Table 2.** Comparison of intradermal and intramuscular AZD1222 booster immunogenicity in  
 428 healthy adult completing 2-dose CoronaVac

	<b>ID</b>	<b>IM</b>	<b>GM Ratio</b>
	<b>GM (95% CI)</b>	<b>GM (95% CI)</b>	<b>(95% CI)</b>
<b>Day 14</b>	N=50	N=100	
• Anti-S-RBD (BAU/mL)	2037.1 (1770.9-2343.2)	2043.2 (1824.5-2288.2)	0.99 (0.83-1.20)
• sVNT-Delta (% inhibition)	95.5 (94.2-96.8)	94.7 (92.4-97.1)	1.01 (0.97-1.04)
• sVNT-WT (% inhibition)	94.8 (94.0-95.6)	96.7 (94.9-98.4)	0.98 (0.96-1.01)
<b>Day 28</b>	N=50	N=24	
• Anti-S-RBD (BAU/mL)	1084.9 (970-1213.4)	1499.5 (1166.6-1927.4)	0.72 (0.57-0.91)
• sVNT-Delta (% inhibition)	93.7 (91.9-95.5)	88.5 (80.1-97.7)	1.06 (0.99-1.14)
• sVNT-WT (% inhibition)	93.7 (92.1-95.4)	91.5 (85.9-97.4)	1.02 (0.98-1.08)
<b>Day 90</b>	N=39	N=99	
• Anti-S-RBD (BAU/mL)	744.6 (650.1-852.9)	909 (802.1-1030.1)	0.82 (0.66-1.02)
• sVNT-Delta (% inhibition)	73.1 (66.7-80.2)	92.8 (90.2-95.4)	0.79 (0.73-0.85)
• sVNT-WT (% inhibition)	81.9 (76.2-88.0)	94.6 (92.4-96.9)	0.87 (0.82-0.92)
	<b>% (95% CI)</b>	<b>% (95% CI)</b>	<b>% difference (95% CI)</b>
<b>Day 14</b>	N=50	N=100	
• Anti-S-RBD $\geq$ 506 BAU/ml <sup>†</sup>	100.0 (92.8-100.0)	97.0 (91.5-99.4)	3.0 (-0.3 to 6.3)
• sVNT-Delta $\geq$ 80% inhibition	98.0 (89.1-99.9)	93.8 (86.9-97.6)	4.2 (-2.0 to 10.5)
• sVNT-WT $\geq$ 80% inhibition	100.0 (92.8-100.0)	95.8 (89.7-98.9)	4.2 (0.01 to 8.2)
<b>Day 28</b>	N=50	N=24	
• Anti-S-RBD $\geq$ 506 BAU/ml <sup>†</sup>	98.0 (89.4-99.9)	96.0 (79.6-99.8)	2.0 (-6.6 to 10.6)
• sVNT-Delta $\geq$ 80% inhibition	98.0	91.7	6.3

	(89.4-99.9)	(73.0-98.9)	(-5.4 to 18.1)
• sVNT-WT $\geq$ 80% inhibition	98.0 (89.4-99.9)	91.7 (73.0-98.9)	6.3 (-5.4 to 18.1)
<b>Day 90</b>	N=39	N=99	
• Anti-S-RBD $\geq$ 506 BAU/ml <sup>†</sup>	79.5 (63.5-90.7)	83.8 (75.1-90.5)	-4.4 (-18.9 to 10.2)
• sVNT-Delta $\geq$ 80% inhibition	52.6 (35.8-69)	89.9 (82.2-95)	-37.3 (-54.2 to -20.3)
• sVNT-WT $\geq$ 80% inhibition	68.4 (51.3-82.5)	90.9 (83.4-95.7)	-22.5 (-38.3 to -6.7)


429

430 Anti-S-RBD: anti Spike receptor binding domain, BAU: Binding-antibody unit, GM: Geometric  
 431 mean, ID: intradermal, IM: intramuscular, sVNT-delta: Surrogate virus neutralization test against  
 432 delta strain, sVNT-WT: Surrogate virus neutralization test against wild type

433 <sup>†</sup>Anti-S-RBD IgG 506 BAU/ml correlated with 80% vaccine efficacy as reported by Feng, et al  
 434 [17].

435

436



437


438

439 **Figure 1.** Solicited reactogenicity within 7 days of ID and IM AZD1222 booster after 2-dose

440 CoronaVac in healthy adult.

441 ID: intradermal, IM: intramuscular

442




443

444 **Figure 2.** Comparison of sVNT % inhibition against delta strain at day 0, 14, 28, and 90 of ID  
445 and IM AZD1222 booster after 2-dose of CoronaVac in healthy adult.

446 ID: intradermal, IM: intramuscular, sVNT: Surrogate virus neutralization test


447

448 (A) SNMO-specific T cell response



449

450 (B) RBD-specific B cell response



451

452

453 **Figure 3.** ELISpot assay at day 0, day 28, and day 90 of ID and IM AZD1222 booster in healthy  
454 adult completing 2-dose CoronaVac: (A) Interferon- $\gamma$  ELISpot response to SNMO overlapping  
455 peptides of SARS-CoV-2, (B) RBD-specific IgG ELISpot assay.

456 ID: intradermal, IM: intramuscular, RBD: receptor binding domain, SFU: spot forming unit,

457 SNMO: Spike (S) nucleoprotein (N), membrane protein (M), and open reading frame proteins

458 (O) of SARS-CoV-2

459

460 **Supplementary Table 1.** Solicited reactogenicity within 7 days of ID and IM AZD1222 booster  
 461 after 2-dose CoronaVac in healthy adult.

<b>Reactogenicity, n (%)</b>	<b>ID (N=100)</b>	<b>IM (N=100)</b>	<b>P-value</b>
<b>Local reactogenicity</b>			
<b>Pain</b>	<b>43 (43)</b>	<b>82 (82)</b>	<b>&lt;0.001*</b>
• Mild	41 (41)	67 (67)	
• Moderate	2 (2)	13 (13)	
• Severe	0	2 (2)	
• Duration (days), median (IQR)	2 (1-4)	3 (2-5)	0.12
<b>Swelling</b>	<b>17 (17)</b>	<b>3 (3)</b>	<b>0.002*</b>
• Mild	15 (15)	1 (1)	
• Moderate	1 (1)	2 (2)	
• Severe	1 (1)	0	
• Duration (days), median (IQR)	6 (5-8)	4 (3-6)	0.28
<b>Redness</b>	<b>53 (53)</b>	<b>3 (3)</b>	<b>&lt;0.001*</b>
• Mild	47 (47)	0 (0)	
• Moderate	5 (5)	2 (2)	
• Severe	1 (1)	1 (1)	
• Duration (days), median (IQR)	4 (3-6)	5 (1-6)	0.35
<b>Systemic reactogenicity</b>			
<b>Fever (BT≥38°C)</b>	<b>0</b>	<b>27 (27)</b>	<b>NA</b>
• Mild	0	10 (10)	
• Moderate	0	12 (12)	
• Severe	0	5 (5)	
• Duration (days), median (IQR)	-	2 (1-2)	NA
<b>Feverish</b>	<b>18 (18)</b>	<b>37 (37)</b>	<b>0.003*</b>
• Mild	16 (16)	27 (27)	
• Moderate	2 (2)	10 (10)	
• Duration (days), median (IQR)	1 (1-2)	1 (1-2)	0.93
<b>Headache</b>	<b>27 (27)</b>	<b>64 (64)</b>	<b>&lt;0.001*</b>
• Mild	17 (17)	37 (37)	
• Moderate	10 (10)	24 (24)	

• Severe	0	3 (3)	
• Duration (days), median (IQR)	2 (1-2)	2 (1-3)	0.15
<b>Fatigue</b>	<b>40 (40)</b>	<b>68 (68)</b>	<b>&lt;0.001*</b>
• Mild	36 (36)	42 (42)	
• Moderate	4 (4)	22 (22)	
• Severe	0 (0)	4 (4)	
• Duration (days), median (IQR)	1 (1-2)	2 (2-3)	0.61
<b>Myalgia</b>	<b>30 (30)</b>	<b>69 (69)</b>	<b>&lt;0.001*</b>
• Mild	27 (27)	35 (35)	
• Moderate	3 (3)	31 (31)	
• Severe	0 (0)	3 (3)	
• Duration (days), median (IQR)	2 (2-3)	2 (2-3)	0.60
<b>Arthralgia</b>	<b>12 (12)</b>	<b>21 (21)</b>	<b>0.09</b>
• Mild	8 (8)	15 (15)	
• Moderate	4 (4)	5 (5)	
• Severe	0 (0)	1 (1)	
• Duration (days), median (IQR)	2 (2-3)	2 (1-2)	0.06
<b>Vomiting</b>	<b>0</b>	<b>4 (4)</b>	<b>NA</b>
• Mild	0	4 (4)	
• Moderate	0	0 (0)	
• Severe	0	0 (0)	
• Duration (days), median (IQR)	0	1 (1-1)	NA
<b>Diarrhea</b>	<b>9 (9)</b>	<b>12 (12)</b>	<b>0.49</b>
• Mild	8 (8)	11 (11)	
• Moderate	1 (1)	1 (1)	
• Duration (days), median (IQR)	1 (1-3)	1 (1-2)	0.43

462

463 ID: intradermal, IM: intramuscular

464 \*p < 0.05

465



466



467



468 **Supplementary Figure 1.** Photography of local reactivity in participants receiving  
469 intradermal AZD1222 booster after completing 2-dose CoronaVac: (A) local reactivity in  
470 participants: i-ii) erythematous patch at injection site at day 4, iii) residual post inflammatory

471 hyperpigmented macule and iv) erythematous patch at injection site at day 28 and (B) a serial  
472 photography day 1-7 in single participant: Day 1 erythematous patch at injection site, Day 2  
473 central swelling on erythematous patch, Day 3-6 blister forming at central of erythematous patch,  
474 and Day 7 dry blister with necrotic crust on erythematous base.

475 **References**

- 476 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from:  
477 <https://covid19.who.int/>. Accessed date 28 November, 2021.
- 478 2. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness  
479 of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med* 2021.  
480 <https://doi.org/10.1056/NEJMoa2107715>
- 481 3. Hitchings MDT, Ranzani OT, Torres MSS, de Oliveira SB, Almiron M, Said R, et al.  
482 Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2  
483 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. *Lancet Reg  
484 Health Am* 2021:100025. <https://doi.org/10.1016/j.lana.2021.100025>
- 485 4. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T,  
486 Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern  
487 than natural infection. *Lancet Infect Dis* 2021. [https://doi.org/10.1016/S1473-3099\(21\)00568-5](https://doi.org/10.1016/S1473-3099(21)00568-5)
- 488 5. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and  
489 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral  
490 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-  
491 inferiority trial. *Lancet* 2021;398:856-69. [https://doi.org/10.1016/S0140-6736\(21\)01694-9](https://doi.org/10.1016/S0140-6736(21)01694-9)
- 492 6. Benning L, Tollner M, Hidmark A, Schaier M, Nussbag C, Kalble F, et al. Heterologous  
493 ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses  
494 among Health Care Workers. *Vaccines (Basel)* 2021;9. <https://doi.org/10.3390/vaccines9080857>
- 495 7. Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal Vaccination:  
496 A Potential Tool in the Battle Against the COVID-19 Pandemic? *Risk Manag Healthc Policy*  
497 2021;14:2079-87. <https://doi.org/10.2147/RMHP.S309707>

- 498 8. Hettinga J, Carlisle R. Vaccination into the Dermal Compartment: Techniques,  
499 Challenges, and Prospects. *Vaccines (Basel)* 2020;8. <https://doi.org/10.3390/vaccines8030534>
- 500 9. Egunsola O, Clement F, Taplin J, Mastikhina L, Li JW, Lorenzetti DL, et al.  
501 Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines:  
502 A Systematic Review and Meta-analysis. *JAMA Netw Open* 2021;4:e2035693.  
503 <https://doi.org/10.1001/jamanetworkopen.2020.35693>
- 504 10. World Health O. Polio vaccines: WHO position paper, March 2016-recommendations.  
505 *Vaccine* 2017;35:1197-9. <https://doi.org/10.1016/j.vaccine.2016.11.017>
- 506 11. World Health O. WHO Expert Consultation on Rabies. Second report. World Health  
507 Organ Tech Rep Ser 2013:1-139, back cover.
- 508 12. World Health O. Rabies vaccines: WHO position paper, April 2018 - Recommendations.  
509 *Vaccine* 2018;36:5500-3. <https://doi.org/10.1016/j.vaccine.2018.06.061>
- 510 13. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.  
511 Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273  
512 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv  
513 2021:2021.07.27.21261116. <https://doi.org/10.1101/2021.07.27.21261116>
- 514 14. Intapiboon PS, P.; Ongarj, J.; Surasombatpattana, S.; Uppanisakorn, S.;  
515 Mahasirimongkol, S.; Sawaengdee, W.; Phumiamorn, S.; Sapsutthipas, S.; Sangsupawanich, P.;  
516 Chusri, S.; Pinpathomrat, N. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA  
517 Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.  
518 *Vaccines* 2021. <https://doi.org/10.3390/vaccines9121375>

- 519 15. Singhatiraj E, Pongpirul K, Jongkaewwattana A, Hirankarn N. Intradermal ChAdOx1  
520 Vaccine Following Two CoronaVac Shots: A Case Report. *Vaccines* 2021;9:990.  
521 <https://doi.org/10.3390/vaccines9090990>
- 522 16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et  
523 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*  
524 2020;26:1033-6. <https://doi.org/10.1038/s41591-020-0913-5>
- 525 17. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection  
526 against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 2021.  
527 <https://doi.org/10.1038/s41591-021-01540-1>
- 528 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus  
529 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein  
530 interaction. *Nat Biotechnol* 2020;38:1073-8. <https://doi.org/10.1038/s41587-020-0631-z>
- 531 19. U.S. Department of Health and Human Services F, CBER. Guidance for Industry  
532 Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive  
533 Vaccine Clinical Trials September 2007 [Available from:  
534 <https://www.fda.gov/media/73679/download>. Accessed date 30 November, 2021.
- 535 20. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection  
536 against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine* 2021.  
537 <https://doi.org/10.1038/s41591-021-01540-1>
- 538 21. Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijns C, et al.  
539 Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A  
540 systematic review and meta-analysis. *Travel Med Infect Dis* 2020;37:101868.  
541 <https://doi.org/10.1016/j.tmaid.2020.101868>

- 542 22. Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al.  
543 Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273  
544 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021.  
545 <https://doi.org/10.1101/2021.07.27.21261116>
- 546 23. Noh JY, Jeong HW, Kim JH, Shin EC. T cell-oriented strategies for controlling the  
547 COVID-19 pandemic. Nat Rev Immunol 2021. <https://doi.org/10.1038/s41577-021-00625-9>
- 548 24. Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, et al.  
549 Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific  
550 Immune Response. Front Immunol 2021;12:645210. <https://doi.org/10.3389/fimmu.2021.645210>
- 551 25. Jahnmatz P, Sundling C, Makower B, Sonden K, Farnert A, Ahlborg N. Multiplex  
552 analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot. J  
553 Immunol Methods 2020;478:112715. <https://doi.org/10.1016/j.jim.2019.112715>
- 554 26. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of  
555 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2  
556 mRNA Vaccine. Front Immunol 2021;12:740708. <https://doi.org/10.3389/fimmu.2021.740708>
- 557 27. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of  
558 SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months  
559 after the infection. Med (N Y) 2021;2:281-95 e4. <https://doi.org/10.1016/j.medj.2021.02.001>
- 560 28. Angsuwatcharakon P, Ratananpinit N, Yoksan S, Saengseesom W, Sriaksorn R,  
561 Raksahket N, et al. Immunogenicity and safety of two-visit, intradermal pre-exposure rabies  
562 prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis  
563 vaccine in children living in rabies and Japanese encephalitis endemic country. Vaccine  
564 2020;38:5015-20. <https://doi.org/10.1016/j.vaccine.2020.05.054>

- 565 29. Fritz TM, Trueb RM. [BCG ulcer. Rapid healing with topical INH powder]. *Hautarzt*  
566 2002;53:816-8. <https://doi.org/10.1007/s00105-002-0367-3>
- 567 30. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and  
568 intramuscular administration of hepatitis B vaccine in neonates. *Indian J Gastroenterol*  
569 2001;20:94-6.
- 570 31. Blanchet K, Mallard G, Moret E, Sun J. Sanctioned countries in the global COVID-19  
571 vaccination campaign: the forgotten 70. *Confl Health* 2021;15:69.  
572 <https://doi.org/10.1186/s13031-021-00404-2>
- 573 32. Perry M, Akbari A, Cottrell S, Gravenor MB, Roberts R, Lyons RA, et al. Inequalities in  
574 coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales,  
575 UK. *Vaccine* 2021. <https://doi.org/10.1016/j.vaccine.2021.09.019>
- 576 33. Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in  
577 Brazilian elderly. *Rev Bras Epidemiol* 2021;24:e210041. <https://doi.org/10.1590/1980-549720210041>
- 579 34. Hannah Ritchie EM, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban  
580 Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus  
581 Pandemic (COVID-19): Our World in Data; 2020 [cited 2021 26 sep 2021]. Available from:  
582 <https://ourworldindata.org/covid-vaccinations>. Accessed date 26 September, 2021.
- 583 35. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused  
584 review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. *Int*  
585 *Immunopharmacol* 2021;100:108162. <https://doi.org/10.1016/j.intimp.2021.108162>
- 586 36. Schweiger M. Intradermal covid-19 vaccination could solve supply problems. *BMJ*  
587 2021;374:n1980. <https://doi.org/10.1136/bmj.n1980>

- 588 37. Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences  
589 and age. *Womens Health (Lond)* 2021;17:17455065211022262.  
590 <https://doi.org/10.1177/17455065211022262>
- 591 38. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG  
592 antibody between male and female COVID-19 patients: A possible reason underlying different  
593 outcome between sex. *J Med Virol* 2020;92:2050-4. <https://doi.org/10.1002/jmv.25989>
- 594 39. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple  
595 protein-based surrogate neutralization assay for SARS-CoV-2. *JCI Insight* 2020;5.  
596 <https://doi.org/10.1172/jci.insight.142362>
- 597 40. Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke GJ, Yerly S, et al. Validation and  
598 clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). *Emerg*  
599 *Microbes Infect* 2020;9:2394-403. <https://doi.org/10.1080/22221751.2020.1835448>
- 600 41. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, et al.  
601 Evaluation of a commercially-available surrogate virus neutralization test for severe acute  
602 respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis*  
603 2021;99:115294. <https://doi.org/10.1016/j.diagmicrobio.2020.115294>